Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial

By afschroeder • February 11, 2026

Bishop CW, Ashfaq A, Choe J, Strugnell SA, Johnson LL, Norris KC, Sprague SM. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026;57(1):109-119. doi: 10.1159/000546615. Epub 2025 Jun 4. PMID: 40466630; PMCID: PMC12193742.

Tags: end-stage kidney disease, Extended-release calcifediol, General Internal Medicine, Hemodialysis, Parathyroid hormone, Publications, secondary hyperparathyroidism

Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right Atrial Rupture

Makaroff KE, Hampilos K, Sayed S, Emert B, Hu X, Nsair A, Kwon M, Middlekauff H. Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right[...]

Long COVID Persistence and Surveillance Gaps Across 58 US Hospitals

Tian J, Azhir A, Decaro M, Chau N, Hügel J, Morris M, Cheng J, Fard P, Bassett IV, Bell DS, Bernstam EV, Visweswaran S, Klann[...]

Use of Evidence-Based Type 2 Diabetes Preventive Therapies and Rates of Progression to Diabetes Among Veterans with Prediabetes by Race and Ethnicity, 2010-2019

Ly DP, Washington DL, Shekelle PG, Lee ML, Moin T. Use of Evidence-Based Type 2 Diabetes Preventive Therapies and Rates of Progression to Diabetes Among[...]